TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS).
Cancers (Basel)
; 15(10)2023 May 12.
Article
in En
| MEDLINE
| ID: mdl-37345075
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Etiology_studies
/
Risk_factors_studies
Language:
En
Journal:
Cancers (Basel)
Year:
2023
Document type:
Article
Affiliation country:
Alemania
Country of publication:
Suiza